BR112015025954A2 - moduladores do receptor de progesterona para utilização na terapia de fibroides uterinos - Google Patents

moduladores do receptor de progesterona para utilização na terapia de fibroides uterinos

Info

Publication number
BR112015025954A2
BR112015025954A2 BR112015025954A BR112015025954A BR112015025954A2 BR 112015025954 A2 BR112015025954 A2 BR 112015025954A2 BR 112015025954 A BR112015025954 A BR 112015025954A BR 112015025954 A BR112015025954 A BR 112015025954A BR 112015025954 A2 BR112015025954 A2 BR 112015025954A2
Authority
BR
Brazil
Prior art keywords
receptor modulators
progesterone receptor
therapy
uterine fibroid
uterine fibroids
Prior art date
Application number
BR112015025954A
Other languages
English (en)
Inventor
Dacquin Annie
Bestel Elke
Loumaye Ernest
Jean Florence
Osterloh Ian
Original Assignee
Preglem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Preglem Sa filed Critical Preglem Sa
Publication of BR112015025954A2 publication Critical patent/BR112015025954A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • H—ELECTRICITY
    • H05—ELECTRIC TECHNIQUES NOT OTHERWISE PROVIDED FOR
    • H05K—PRINTED CIRCUITS; CASINGS OR CONSTRUCTIONAL DETAILS OF ELECTRIC APPARATUS; MANUFACTURE OF ASSEMBLAGES OF ELECTRICAL COMPONENTS
    • H05K9/00—Screening of apparatus or components against electric or magnetic fields
    • H05K9/0007—Casings
    • H05K9/0052—Shielding other than Faraday cages

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Power Engineering (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Percussion Or Vibration Massage (AREA)

Abstract

resumo “moduladores do receptor de progesterona para utilização na terapia de fibroides uterinos” a presente invenção refere-se a uma terapia de longo prazo incluindo ciclos de tratamento repetidos de acetato de ulipristal, ou qualquer metabólito do mesmo, para o tratamento de fibroides uterinos. a presente invenção refere-se também a uma terapia combinada aplicando acetato de ulipristal com uma progestina, a fim de melhorar o tratamento atualmente utilizado para fibroides uterinos.
BR112015025954A 2013-04-10 2014-04-09 moduladores do receptor de progesterona para utilização na terapia de fibroides uterinos BR112015025954A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HUP1300211 2013-04-10
PCT/IB2014/060558 WO2014167510A2 (en) 2013-04-10 2014-04-09 Progesteron receptor modulators for use in the therapy of uterine fibroids

Publications (1)

Publication Number Publication Date
BR112015025954A2 true BR112015025954A2 (pt) 2017-07-25

Family

ID=89707373

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015025954A BR112015025954A2 (pt) 2013-04-10 2014-04-09 moduladores do receptor de progesterona para utilização na terapia de fibroides uterinos

Country Status (19)

Country Link
US (2) US10172869B2 (pt)
EP (1) EP2983672A2 (pt)
JP (1) JP2016516764A (pt)
KR (1) KR20150139919A (pt)
CN (1) CN105120874A (pt)
AR (1) AR095831A1 (pt)
AU (1) AU2014252196B2 (pt)
BR (1) BR112015025954A2 (pt)
CA (1) CA2907674A1 (pt)
EA (1) EA030831B1 (pt)
HK (1) HK1221169A1 (pt)
IL (1) IL241380B (pt)
MX (1) MX2015014199A (pt)
MY (1) MY181448A (pt)
NZ (1) NZ712984A (pt)
SG (1) SG11201507260QA (pt)
UY (1) UY35528A (pt)
WO (1) WO2014167510A2 (pt)
ZA (1) ZA201507535B (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113797210A (zh) * 2015-05-18 2021-12-17 拜耳医药股份有限公司 选择性孕酮受体调节剂(sprm)方案
CN118436663A (zh) * 2024-04-25 2024-08-06 浙江大学 醋酸乌利司他在制备抗纤维化药物中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3920805A (en) 1971-12-09 1975-11-18 Upjohn Co Pharmaceutical devices and method
US4155991A (en) 1974-10-18 1979-05-22 Schering Aktiengesellschaft Vaginal ring
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
US3995633A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal Medicament dispensing device
US3995634A (en) 1975-12-02 1976-12-07 The Procter & Gamble Company Vaginal cavity dispensing means and method
US3991760A (en) 1975-12-02 1976-11-16 The Procter & Gamble Company Vaginal medicament dispensing means
US4286587A (en) 1978-10-11 1981-09-01 Alza Corporation Vaginal drug delivery system made from polymer
US4292965A (en) 1978-12-29 1981-10-06 The Population Council, Inc. Intravaginal ring
US4250611A (en) 1979-04-19 1981-02-17 Alza Corporation Process for making drug delivery device with reservoir
US4596576A (en) 1984-10-12 1986-06-24 Akzo N.V. Release system for two or more active substances
NL8500470A (nl) 1985-02-19 1986-09-16 Achel Homesteel Pvba Intravaginaal orgaan.
US4954490A (en) 1988-06-23 1990-09-04 Research Triangle Institute 11 β-substituted progesterone analogs
FI95768C (fi) 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5929262A (en) 1995-03-30 1999-07-27 The United States Of America As Represented By The Department Of Health And Human Services Method for preparing 17α-acetoxy-11β-(4-N, N-dimethylaminophyl)-19-Norpregna-4,9-diene-3, 20-dione, intermediates useful in the method, and methods for the preparation of such intermediates
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
FR2827517B1 (fr) 2001-07-23 2003-10-24 Bioalliance Pharma Systemes therapeutiques bioadhesifs a liberation prolongee
ES2212912B1 (es) 2003-01-22 2005-10-01 Crystal Pharma, S.A. Procedimiento para la obtencion de 17alfa-acetoxi-11beta-(4-n,n-dimetilaminofenil)-19-norpregna-4,9-dien-3,20-diona.
EP1613640A4 (en) 2003-02-28 2010-05-19 Us Gov Health & Human Serv PROCESS FOR PREPARING 17 ALPHA-ACETOXY-11 BETA- (4-N, N-DIMETHYLAMINOPHENYL) -19-NORPREGNA-4,9-DIENE-3,20-DION, INTERMEDIATE PRODUCTS AND METHOD OF MANUFACTURING THESE INTERMEDIATE PRODUCTS
US20050215535A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/progestin treatment
US20050215536A1 (en) * 2004-03-24 2005-09-29 Kristof Chwalisz Sequential SPRM/ progestin treatment
BRPI0513141A (pt) 2004-07-09 2008-04-29 Population Council Inc composição para anel vaginal, e, processo de contracepção a longo prazo
WO2007103510A2 (en) 2006-03-08 2007-09-13 Danco Laboratories Llc Methods, dosing regimens & medications using anti-progestational agents for the treatment of disorders
EP3693376A1 (en) 2006-10-24 2020-08-12 Allergan Pharmaceuticals International Limited Compositions for suppressing endometrial proliferation
MX2009006912A (es) 2006-12-28 2009-08-12 Repros Therapeutics Inc Metodos y formulaciones para biodisponibilidad mejorada de antiprogestinas.
US8299050B2 (en) * 2008-01-29 2012-10-30 Laboratoire Hra-Pharma Method for treating uterine fibroids
US8512745B2 (en) * 2008-12-08 2013-08-20 Laboratoire Hra Pharma Ulipristal acetate tablets
CN102727457B (zh) * 2011-04-08 2014-05-28 华润紫竹药业有限公司 稳定的醋酸优力司特制剂

Also Published As

Publication number Publication date
MX2015014199A (es) 2016-06-21
MY181448A (en) 2020-12-22
AR095831A1 (es) 2015-11-11
ZA201507535B (en) 2017-02-22
HK1221169A1 (zh) 2017-05-26
UY35528A (es) 2014-09-30
US20160038510A1 (en) 2016-02-11
IL241380B (en) 2018-11-29
EA201591892A1 (ru) 2016-02-29
CA2907674A1 (en) 2014-10-16
AU2014252196A1 (en) 2015-10-29
JP2016516764A (ja) 2016-06-09
AU2014252196B2 (en) 2019-05-16
WO2014167510A2 (en) 2014-10-16
EA030831B1 (ru) 2018-10-31
US10172869B2 (en) 2019-01-08
KR20150139919A (ko) 2015-12-14
IL241380A0 (en) 2015-11-30
SG11201507260QA (en) 2015-10-29
US20190262361A1 (en) 2019-08-29
EP2983672A2 (en) 2016-02-17
WO2014167510A3 (en) 2015-02-19
CN105120874A (zh) 2015-12-02
NZ712984A (en) 2020-07-31

Similar Documents

Publication Publication Date Title
FR24C1001I1 (fr) Anticorps anti-pd1 et leur utilisation en tant qu'agents thérapeutiques et de diagnostic
MY173148A (en) Platelet lysate gel
BR112015020911A2 (pt) anticorpo, uso de uma combinação e método de tratamento
BR112015030387A2 (pt) compostos de pirazol como moduladores de fshr e usos dos mesmos
BR112015033069A2 (pt) moduladores de receptor do hormônio de crescimento
EA201591196A1 (ru) Композиции и способы для трансдермальной доставки гормонов и других лекарственных средств
TWD158438S (zh) 影像顯示器
CL2016000019A1 (es) Compuestos derivados de dihidroxifenilo deuterado o una sal de los mismos; composición farmacéutica que los comprende y su uso para el tratamiento de trastornos mediados por neurotransmisores tales como hipotensión, trastornos del sueño, enfermedad de alzheimer y depresión.
EP3033350A4 (en) Progesterone phosphate analogs and uses related thereto
FR3006145B1 (fr) Dispositif de distribution de graines a l'unite
FR3002123B1 (fr) Dispositif de distribution comprenant une composition aqueuse sous forme de gel ou de creme epaisse
TWD173920S (zh) 攪拌器的攪拌體
BR112015025954A2 (pt) moduladores do receptor de progesterona para utilização na terapia de fibroides uterinos
BR112014030406A2 (pt) combinação de canabidiol fitocanabinoide com hipotermia terapêutica
TWD161175S (zh) 汽車診斷裝置
TWD158437S (zh) 影像顯示器
CO7151508A2 (es) Moduladores de los receptores de progesterona para uso en la prevención ó en el tratamiento de enfermedades mediadas por andrógenos
Adhiti Sustainable Development in Education: a case for ICT
ITTO20130512A1 (it) Benda elastica, particolarmente per l'impiego nel trattamento dell'edema da insufficienza veno-linfatica
TH1501001422A (th) อนุพันธ์ไพราโซลคาร์บอกซาไมด์ในฐานะ taar โมดูเลเตอร์สำหรับใช้ในการรักษา ความผิดปกติหลายชนิดอย่างเช่นภาวะซึมเศร้า, เบาหวาน และโรคพาร์กินสัน
TWD158660S (zh) 瓶子
CN302489041S (zh) 汽车电源控制盒
CN302467076S (zh) 汽车用中控面板
CN302231352S (zh) 加速器(jcth)
GB201310748D0 (en) Student's clinic

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL